Short Interest in Apollo Endosurgery, Inc. (NASDAQ:APEN) Increases By 59.0%

Apollo Endosurgery, Inc. (NASDAQ:APENGet Rating) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 948,200 shares, a growth of 59.0% from the March 31st total of 596,500 shares. Based on an average daily trading volume, of 146,900 shares, the short-interest ratio is presently 6.5 days.

Several analysts have weighed in on APEN shares. Zacks Investment Research cut Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, February 1st. Stifel Nicolaus reduced their price target on Apollo Endosurgery from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, February 23rd. Finally, Piper Sandler cut their price objective on Apollo Endosurgery from $14.00 to $12.00 in a research report on Wednesday, February 23rd. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.50.

NASDAQ:APEN opened at $5.43 on Friday. The stock has a 50-day simple moving average of $6.01 and a two-hundred day simple moving average of $7.04. Apollo Endosurgery has a 52-week low of $4.52 and a 52-week high of $10.39. The company has a debt-to-equity ratio of 0.87, a current ratio of 7.92 and a quick ratio of 7.09.

Apollo Endosurgery (NASDAQ:APENGet Rating) last announced its quarterly earnings data on Tuesday, February 22nd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.07). The business had revenue of $16.17 million during the quarter, compared to analysts’ expectations of $16.17 million. Apollo Endosurgery had a negative net margin of 39.19% and a negative return on equity of 148.35%. During the same quarter in the previous year, the firm earned ($0.14) earnings per share. As a group, equities analysts predict that Apollo Endosurgery will post -0.87 earnings per share for the current year.

In other news, CFO Jeffrey G. Black purchased 15,000 shares of the company’s stock in a transaction dated Friday, February 25th. The shares were purchased at an average price of $5.48 per share, with a total value of $82,200.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 30.00% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of Apollo Endosurgery during the 4th quarter valued at $41,000. Lazard Asset Management LLC grew its position in Apollo Endosurgery by 57.2% during the 4th quarter. Lazard Asset Management LLC now owns 6,142 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 2,236 shares during the period. Waypoint Capital Advisors LLC acquired a new stake in Apollo Endosurgery during the 1st quarter worth about $58,000. Barclays PLC grew its position in Apollo Endosurgery by 384.1% during the 3rd quarter. Barclays PLC now owns 6,772 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 5,373 shares during the period. Finally, Sciencast Management LP acquired a new stake in Apollo Endosurgery during the 1st quarter worth about $80,000. 91.54% of the stock is currently owned by institutional investors.

Apollo Endosurgery Company Profile (Get Rating)

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope.

See Also

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with's FREE daily email newsletter.